Although GLP-1/GIP co-agonists are one of the most promising drugs to treat obesity and diabetes and have been shown to reduce fasting cholesterol and triglycerides in T2D patients [8, 9], GIP-dependent contributions to metabolic benefits achieved with this combinatorial therapy remain unclear. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.